← All stocks

Elevance Health

ELV No buying or selling
CIK 0001156039 #171 in the set updated 17 Sep 2026
Bought (1 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (1 mo)
$0.00
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$0.00
0 of 0 sales
Net
$0.00
$0.00 against sales at will

By person

21 insiders · 0 transactions
39.5×

Gail Boudreaux holds 39.5 times base salary in stock. $63.33M of shares against $1.60M in salary for 2025.

Salary from the company's own proxy. The shares are what Gail Boudreaux last reported holding, valued at $368.25, the price Common Stock was last bought or sold at on the open market here, on 17 Jul 2026.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
BOUDREAUX GAIL
President and CEO
171,976
0.0793%
$63.33M
+35.7%
Norwood Felicia F
EVP &Chief Health Benefits Ofr
38,838
0.0179%
$14.30M
+42.2%
Kaye Mark
EVP & CFO
32,037
0.0148%
$11.80M
+39.0%
Haytaian Peter D
EVP & Pres Carelon & CarelonRx
27,222
0.0126%
$10.02M
+44.1%
LAVU RATNAKAR
EVP & Chief Digital Info Ofr
16,149
0.0074%
$5.95M
+486.0%
Todt Blair Williams
EVP, CLO & CAO
15,631
0.0072%
$5.76M
−2.5%
HAY LEWIS III
Director
12,070
0.0056%
$4.44M
+10.7%
Kendrick Charles Morgan JR
EVP & President, Commercial
11,791
0.0054%
$4.34M
−25.7%
PERU RAMIRO G
Director
10,908
0.0050%
$4.02M
+24.7%
Dixon Robert L JR
Director
10,734
0.0049%
$3.95M
+10.4%
CLARK R KERRY
Director
9,640
0.0044%
$3.55M
+6.6%
Wessling Erin M
EVP & Chief Legal Officer
7,230
0.0033%
$2.66M
+70.5%
Schneider Ryan M.
Director
7,163
0.0033%
$2.64M
+19.4%
Craig Ryan R
EVP & Chief HR Officer
6,530
0.0030%
$2.40M
+95.5%
Neri Antonio F
Director
5,488
0.0025%
$2.02M
+26.9%
Jallal Bahija
Director
5,351
0.0025%
$1.97M
+27.8%
COLLIS STEVEN H
Director
4,202
0.0019%
$1.55M
DeVore Susan D.
Director
4,065
0.0019%
$1.50M
+139.0%
Penczek Ronald W
CAO & Controller
3,740
0.0017%
$1.38M
+105.6%
STRABLE-SOETHOUT DEANNA D
Director
2,209
0.0010%
$813.46K
+111.4%
SCHULMAN AMY W
Director
781
0.0004%
$287.60K
+2,904%

Nothing of that kind in this period.

What was left out

Form 4 filings counted 2
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 493
History held since 5 Oct 2016